Sutro Biopharma, Boehringer announce application of Sutro’s technology

Boehringer Ingelheim BioXcellence and Sutro Biopharma (STRO) announced that they successfully applied Sutro’s proprietary cell-free expression technology on a commercial scale to manufacture luveltamab tazevibulin, Sutro’s Tubulin FRalpha-targeting antibody-drug conjugate, ADC, designed to treat a broad range of patients with ovarian cancer and other FRalpha expressing cancers. For the first time, the cross-functional teams were able to scale up Sutro’s cell-free protein synthesis platform from a small-scale Good Manufacturing Practice production to a large-scale GMP production marking an industry milestone. All batches of luvelta manufactured in 4,500 L at Boehringer’s large-scale manufacturing facility in Vienna, Austria, met the product quality criteria required for the use in clinical studies.